Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Deciphera reports updated Phase I data for DCC-2618 in GIST

Jaime De Leon
June 8, 2018 3:24 PM UTC

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase I trial.

This year, Deciphera plans to start the Phase III INTRIGUE trial of DCC-2618 as second-line treatment of GIST. The product is also in the Phase III INVICTUS trial in heavily pretreated fourth-line or greater GIST patients...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

American Society of Clinical Oncology

Bayer AG

Deciphera Pharmaceuticals Inc.

Pfizer Inc.